SHARE-BASED COMPENSATION - Option activity (Details) - USD ($) |
3 Months Ended | 12 Months Ended |
|---|---|---|
Mar. 31, 2026 |
Dec. 31, 2025 |
|
| Options outstanding | ||
| Outstanding, vested and expected to vest at the beginning of the period | 227,775 | |
| Outstanding, vested and expected to vest at the end of the period | 227,775 | 227,775 |
| Exercisable | 214,101 | |
| Weighted Average Exercise Price | ||
| Weighted Average Exercise price, Beginning of the period | $ 88.45 | |
| Weighted Average Exercise price, End of the period | 88.45 | $ 88.45 |
| Exercisable | $ 90.28 | |
| Weighted Average Remaining Contractual Term (in years) | ||
| Weighted average contractual life | 6 years 9 months 3 days | 6 years 9 months 3 days |
| Weighted Average Remaining Contractual Term, Exercisable | 6 years 5 months 1 day | |
| Aggregate Intrinsic Value | ||
| Aggregate Intrinsic Value, Beginning of the period | $ 0 | |
| Aggregate Intrinsic Value, End of the period | 0 | $ 0 |
| Aggregate Intrinsic Value, Exercisable | $ 0 |
| X | ||||||||||
- Definition Represents the details pertaining to Aggregate Intrinsic Value. No definition available.
|
| X | ||||||||||
- Definition Represents the details pertaining to Weighted Average Remaining Contractual Term. No definition available.
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|